Clinical Trials
25 trialsNCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06091930 2026-05-07
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
Phase 1 Completed
NCT06187103 2026-04-21
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
Active not recruiting
NCT06681233 2026-03-13
Feasibility Study of CBCT for IGRT in Cancer Patients
Varian, a Siemens Healthineers Company
Phase NA Recruiting
NCT04752215 2026-02-02
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Boehringer Ingelheim
Phase 1 Completed
NCT05001347 2025-12-16
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
Phase 2 Completed
NCT04180371 2025-11-17
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
Phase 1/2 Active not recruiting
NCT04278144 2025-09-15
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Phase 1/2 Terminated
NCT05406167 2025-08-15
PREMIER
RefleXion Medical
Recruiting
NCT06872489 2025-07-23
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
Available
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03549494 2024-02-07
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Catalysis SL
Phase 2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT05961111 2023-07-27
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Recruiting
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT04460456 2022-06-30
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Silverback Therapeutics
Phase 1 Unknown
NCT02045368 2019-08-22
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
IGF Oncology, LLC
Phase 1 Completed
NCT00465725 2009-09-24
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Poniard Pharmaceuticals
Phase 1 Completed
NCT00710697 2009-09-24
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
Poniard Pharmaceuticals
Phase 1 Unknown
NCT00120939 2009-04-03
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics LLC.
Phase 1 Completed